© 2023 GeneDx All rights reserved.
December 1, 2023
GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
November 28, 2023
GeneDx to Participate in 6th Annual Evercore ISI HealthCONx Conference
November 20, 2023
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 30, 2023
GeneDx Reports Third Quarter 2023 Financial Results and Business Highlights
October 9, 2023
GeneDx to Report Third Quarter 2023 Financial Results on Monday, October 30, 2023
September 22, 2023
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 11, 2023
GeneDx Announces Evolution of Executive Leadership Team
September 6, 2023
GeneDx Announces Industry-Leading Accomplishment of 500,000 Clinical Exomes Sequenced
August 21, 2023
GeneDx Announces Data Demonstrating that Whole Exome and Genome Sequencing Report Fewer Variants of Uncertain Significance (VUS) than Multi-Gene Panel Testing Published in Genetics in Medicine
August 8, 2023
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Displaying 1 - 10 of 38